INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

March 11, 2018

Responsive image

ORLANDO, Fla., March 11, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new analysis showing that INVOKANA® (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure…

Category: Precious Metals